应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
09926 康方生物
未开盘 04-15 16:08:08
147.400
+9.500
+6.89%
最高
148.000
最低
138.900
成交量
1,193万
今开
139.800
昨收
137.900
日振幅
6.60%
总市值
1,358亿
流通市值
1,358亿
总股本
9.21亿
成交额
17.26亿
换手率
1.29%
流通股本
9.21亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
康方生物更新2026年3月股份变动月报表，股本维持稳定
公告速递 · 04-08
康方生物更新2026年3月股份变动月报表，股本维持稳定
国金证券：维持康方生物(09926)“买入”评级 临床试验陆续兑现
智通财经 · 04-07
国金证券：维持康方生物(09926)“买入”评级 临床试验陆续兑现
中金：国产创新药产业趋势向好 26年学术领域看点较多
智通财经 · 04-03
中金：国产创新药产业趋势向好 26年学术领域看点较多
异动解读 | 康方生物盘中大涨5.53%，大手买入推动股价上扬
异动解读 · 04-01
异动解读 | 康方生物盘中大涨5.53%，大手买入推动股价上扬
【券商聚焦】交银国际维持康方生物(09926)买入评级 预计其2026年起亏损将快速收窄
金吾财讯 · 03-31
【券商聚焦】交银国际维持康方生物(09926)买入评级 预计其2026年起亏损将快速收窄
【券商聚焦】中信证券：基本医保基金收支和结余整体保持稳健
金吾财讯 · 03-31
【券商聚焦】中信证券：基本医保基金收支和结余整体保持稳健
北水动向|北水成交净卖出24.67亿 港股ETF及石油股遭抛售 腾讯(00700)再获加仓
智通财经 · 03-30
北水动向|北水成交净卖出24.67亿 港股ETF及石油股遭抛售 腾讯(00700)再获加仓
大行评级丨瑞银：康方生物去年下半年业绩逊于预期，目标价降至173.4港元
中金财经 · 03-30
大行评级丨瑞银：康方生物去年下半年业绩逊于预期，目标价降至173.4港元
部分创新药概念股逆市上扬 荣昌生物(09995)涨4.99%
金吾财讯 · 03-30
部分创新药概念股逆市上扬 荣昌生物(09995)涨4.99%
异动解读 | 康方生物盘中大涨7.36%，因出现大手买入
异动解读 · 03-30
异动解读 | 康方生物盘中大涨7.36%，因出现大手买入
康方生物(09926)发布年度业绩，收入同比增长43.9%至30.56亿元
智通财经 · 03-26
康方生物(09926)发布年度业绩，收入同比增长43.9%至30.56亿元
港股生物医药板块涨幅居前，康方生物涨超5%，科伦博泰生物涨超4%
老虎资讯综合 · 03-26
港股生物医药板块涨幅居前，康方生物涨超5%，科伦博泰生物涨超4%
【券商聚焦】交银国际：CXO行情持续回暖 料板块估值倍数合理
金吾财讯 · 03-23
【券商聚焦】交银国际：CXO行情持续回暖 料板块估值倍数合理
【券商聚焦】中国银河：“十五五”首次将生物医药列为国家新兴支柱产业，持续发力研发创新
金吾财讯 · 03-20
【券商聚焦】中国银河：“十五五”首次将生物医药列为国家新兴支柱产业，持续发力研发创新
港股康方生物再涨超4%
每日经济新闻 · 03-16
港股康方生物再涨超4%
港股异动 | 康方生物(09926)再涨超4% 公司首款三抗AK150近日获批临床
智通财经 · 03-16
港股异动 | 康方生物(09926)再涨超4% 公司首款三抗AK150近日获批临床
康方生物03月11日主力净流出492.9万元 散户资金买入
市场透视 · 03-11
康方生物03月11日主力净流出492.9万元 散户资金买入
康方生物三抗登场
动脉网 · 03-11
康方生物三抗登场
港股异动 | 创新药概念股普涨，康方生物、科伦博泰生物涨超9%
老虎资讯综合 · 03-10
港股异动 | 创新药概念股普涨，康方生物、科伦博泰生物涨超9%
港股异动 | 康方生物(09926)早盘涨近8% 全球首创的三特异性抗体新药AK150进入临床
智通财经 · 03-10
港股异动 | 康方生物(09926)早盘涨近8% 全球首创的三特异性抗体新药AK150进入临床
加载更多
公司概况
公司名称：
康方生物
所属市场：
SEHK
上市日期：
--
主营业务：
康方生物科技（开曼）有限公司是一家致力于研究、开发、生产及商业化让全球病人可负担的抗体药的投资控股公司。该公司在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域。该公司的产品主要包括有用于肿瘤领域的开坦尼（卡度尼利，PD-1/CTLA-4）、依达方（依沃西，PD-1/VEGF）、莱法利（AK117，CD47）、普络西（AK109，VEGFR-2）、安尼可（派安普利，PD-1）、科泰莱（塔戈利单抗，PD-L1）和用于代谢及自免领域的伊喜宁（伊努西单抗，PCSK9）、爱达罗（依若奇单抗，IL-12/IL-23）、古莫奇单抗（AK111，IL-17）。
发行价格：
--
{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"康方生物","latestPrice":147.4,"timestamp":1776240488007,"preClose":137.9,"halted":0,"volume":11926921,"delay":0,"changeRate":0.06889050036258158,"floatShares":921000000,"shares":921000000,"eps":-1.416612302941522,"marketStatus":"未开盘","change":9.5,"latestTime":"04-15 16:08:08","open":139.8,"high":148,"low":138.9,"amount":1725791042,"amplitude":0.06599,"askPrice":147.4,"askSize":14000,"bidPrice":147,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":-1.416612302941522,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776303000000},"marketStatusCode":0,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":137.9,"openAndCloseTimeList":[[1776216600000,1776225600000],[1776229200000,1776240000000]],"volumeRatio":1.8222884078323225,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":0.5467,"impliedVolPercentile":0.4211},"requestUrl":"/m/hq/s/09926","defaultTab":"news","newsList":[{"id":"1114779592","title":"康方生物更新2026年3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1114779592","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114779592?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:06","pubTimestamp":1775639206,"startTime":"0","endTime":"0","summary":"康方生物科技（开曼）有限公司于2026年4月8日发布2026年3月股份变动月报。根据公告，截至2026年3月31日，公司注册股本维持在5,000,000,000股，每股面值USD0.00001，注册股本总额为USD50,000，与上月保持一致。公司同时确认于报告期末满足香港联交所对最低公众持股量的要求。该月报由董事夏瑜签署。公司表示将继续遵守香港联交所相关规定，确保公众持股量符合要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625093511","title":"国金证券：维持康方生物(09926)“买入”评级 临床试验陆续兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2625093511","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625093511?lang=zh_cn&edition=full","pubTime":"2026-04-07 16:38","pubTimestamp":1775551094,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，康方生物核心产品在国内商业化快速放量、且具备引领全球临床用药迭代的潜力。维持“买入”评级。国金证券主要观点如下：业绩简评2026年3月26日公司发布2025年业绩公告，公司25年实现收入30.56亿元。展望2026年，随着依沃西一线治疗PD-L1阳性NSCLC适应症、卡度尼利疗法一线治疗胃癌和一线治疗宫颈癌适应症，以及派安普利、伊努西和依若奇全部新增纳入国家医保目录，放量有望迎来进一步加速。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624314016","title":"中金：国产创新药产业趋势向好 26年学术领域看点较多","url":"https://stock-news.laohu8.com/highlight/detail?id=2624314016","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624314016?lang=zh_cn&edition=full","pubTime":"2026-04-03 10:41","pubTimestamp":1775184094,"startTime":"0","endTime":"0","summary":"中金主要观点如下：研发效率、临床资源优势禀赋，国产创新BD加速、量价齐升NMPA和医药魔方统计显示，2026Q1国内创新药BD总金额超600亿美元，超过2024全年、接近2025全年水平1/2；且平均首付款和平均交易规模均创历史新高。在MNC的积极推动下，多个中国创新资产有望在2026年步入上市申报阶段；基于对国内企业创新能力的认可，多个早期平台化对外合作交易陆续达成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2778985437.USD","159992","06978","BK1515","LU1303224171.USD","01276","01877","LU2328871848.SGD","LU0561508036.HKD","06938","LU0634319403.HKD","LU2543165471.USD","LU0348783233.USD","LU0359202008.SGD","LU0359201885.HKD","LU0588546209.SGD","LU0348766576.USD","BK1500","09995","LU1023057109.AUD","LU0348784397.USD","LU1961090484.USD","LU1969619763.USD","LU2476274720.SGD","IE00B5MMRT66.SGD","BK1191","BK1583","LU0540923850.HKD","LU0359201612.USD","LU0348825331.USD","LU1720050803.USD","LU1770034418.SGD","IE00B543WZ88.USD","LU0417516902.SGD","LU2488822045.USD","BK1161","09926","06160","LU0348767384.USD","LU1719994722.HKD","IE00BPRC5H50.USD","LU2399975544.HKD","LU0417516738.SGD","LU0417516571.SGD","BK1588","BK1574","LU0348827113.USD","LU1794554557.SGD","LU0348735423.USD","LU0307460666.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132166488","title":"异动解读 | 康方生物盘中大涨5.53%，大手买入推动股价上扬","url":"https://stock-news.laohu8.com/highlight/detail?id=1132166488","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132166488?lang=zh_cn&edition=full","pubTime":"2026-04-01 11:40","pubTimestamp":1775014801,"startTime":"0","endTime":"0","summary":"康方生物(09926)今日盘中大涨5.53%，引起了市场的广泛关注。消息面上，该股在盘中交易时段出现多次大手买入。根据相关交易数据，在上午不同时间点，康方生物接连出现大额买单，涉及成交量从数万股到近15万股不等，成交金额从数百万到超过两千万港币，这些集中且连续的大手买入直接推动了股价的快速上涨。市场分析认为，机构或大资金的积极买入行为，往往被市场解读为对该公司基本面或未来前景的认可，从而增强了投资者信心，并可能吸引更多资金跟随，共同推升股价。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623371490","title":"【券商聚焦】交银国际维持康方生物(09926)买入评级 预计其2026年起亏损将快速收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2623371490","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623371490?lang=zh_cn&edition=full","pubTime":"2026-03-31 11:08","pubTimestamp":1774926529,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，康方生物 2025年商业版图快速扩大，医保覆盖+新品推动下高增速有望延续至2026年：全年产品销售收入同比增长51.5%至30.33亿元，增量主要来自核心产品卡度尼利和首次纳入医保的依沃西。考虑到收入持续高增和费用率改善，该机构预计2026年起亏损将快速收窄。基于2025年业绩下调2026-27年盈利预测，同时基于依沃西的海内外多项进展，将其全球经PoS调整峰值销售预测从116亿美元上调至132亿元。下调DCF目标价至175港元，维持买入评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977833","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623373124","title":"【券商聚焦】中信证券：基本医保基金收支和结余整体保持稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=2623373124","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623373124?lang=zh_cn&edition=full","pubTime":"2026-03-31 08:59","pubTimestamp":1774918794,"startTime":"0","endTime":"0","summary":"2026年2月医保支出同比增速回升，收支剪刀差有所收窄。该机构预计在医保基金监管力度持续加大，DRG/DIP精细化管理的推动下，2026年全年基金结余率或将延续此前节奏略有提升。医疗健康产业政策改革进入密集期，建议持续关注政策驱动下的医疗健康产业投资机会。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977773","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1564","IE00B543WZ88.USD","03933","HK0000165453.HKD","BK1100","IE00BPRC5H50.USD","BK1161","LU0307460666.USD","LU0634319403.HKD","LU1255011170.USD","LU2399975544.HKD","BK1147","09926","09688","LU0405327494.USD","LU2148510915.USD","LU2476274308.USD","LU1719994722.HKD","BK1588","02196","01789","BK0276","BK1593","LU1770034418.SGD","06160","02228","BK0012","LU1969619763.USD","LU0405327148.USD","600030","LU0348735423.USD","LU2488822045.USD","01530","06821","02367","BK1191","06030","LU1997245177.USD","BK1617","LU0348783233.USD","BK1583","LU2495084118.USD","LU1303224171.USD","01099","LU1115378108.SGD","LU1328615791.USD","BK1515","LU0348766576.USD","BK0028","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623159813","title":"北水动向|北水成交净卖出24.67亿 港股ETF及石油股遭抛售 腾讯(00700)再获加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2623159813","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623159813?lang=zh_cn&edition=full","pubTime":"2026-03-30 17:49","pubTimestamp":1774864148,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月30日港股市场，北水成交净卖出24.67亿港元。北水净买入最多的个股是腾讯 、迅策、康方生物。港股通(沪)活跃成交股港股通(深)活跃成交股腾讯获净买入6.08亿港元。消息面上，腾讯自3月26日起重启回购，26日和27日连续回购两天。山东墨龙、中海油分别遭净卖出509万、7064万港元。北水资金抛售港股ETF，盈富基金、南方恒生科技、恒生中国企业分别遭净卖出38.45亿、13.38亿、11.83亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0488056044.USD","LU1196710195.USD","LU0886674414.USD","IE0003795394.USD","LU0228659784.USD","LU0128522744.USD","LU1226287875.USD","IE00BQXX3D17.EUR","LU0164880469.USD","LU2317271919.USD","SG9999007991.SGD","LU0456846285.SGD","LU0164865239.USD","LU0890818403.SGD","LU1188198961.HKD","LU0675040207.SGD","LU0231483743.USD","LU0516422366.SGD","LU1813983027.USD","LU0880133367.SGD","LU1226288253.USD","LU0235996351.USD","IE00BPRC5H50.USD","LU1282649141.HKD","HSI","LU0828237940.HKD","LU0287142896.SGD","LU0823413660.USD","LU2125910500.SGD","HK0001040168.HKD","LU0211977185.USD","LU0449509016.USD","LU2008162690.USD","LU0348816934.USD","LU1102505762.USD","LU0107464264.USD","LU0169518387.USD","HK0000320264.USD","LU0463099449.HKD","IE00B543WZ88.USD","LU0293314216.USD","LU1691799644.USD","BK1586","LU0396098781.USD","HK0001040143.USD","IE00BGV7N243.SGD","IE00B8HQ1Z84.USD","LU2279701549.SGD","LU1814569148.SGD","LU0791590937.USD","LU0348723411.USD","IE00B067MR52.USD","LU0572944931.SGD","SG9999015986.USD","LU0173614495.USD","LU0228367735.SGD","SG9999001689.USD","LU0049853897.USD","LU0051755006.USD","LU0588545730.USD","BK4570","LU0449515922.USD","LU1868837722.USD","LU0878005551.USD","LU0633140727.USD","LU0611395673.USD","IE00B031J352.USD","LU0972618739.USD","LU1675838814.USD","LU0648948544.HKD","LU0516423091.SGD","LU0589944569.HKD","SG9999014906.USD","IE0032431581.USD","LU0132412106.USD","BK1502","LU1804176565.USD","LU0543330483.HKD","SG9999014898.SGD","LU0821914370.USD","LU0823426308.USD","LU2251237488.HKD","LU0738912210.USD","LU2039709279.SGD","LU1242518857.USD","LU0348805143.USD","LU0594300179.USD","LU0441854154.USD","BK1607","BK4504","LU1961090484.USD","LU0106959298.USD","LU1226287792.SGD","LU1196710351.USD","LU1733274473.HKD","LU2251237306.USD","LU0348783233.USD","LU0348827113.USD","LU0348784397.USD","LU0359201612.USD","LU1439103000.SGD","LU1224709979.USD","LU0061477393.USD","LU1629966141.USD","HK0000352382.USD","IE00BQXX3F31.USD","LU1642822792.SGD","LU0918141705.HKD","LU0011963245.USD","LU1880383440.USD","LU2045819591.USD","LU0163747925.USD","LU0868486357.SGD","LU0633140560.USD","LU0106259558.USD","IE0008369823.USD","LU0572939691.SGD","LU0456827905.SGD","LU1282649810.SGD","LU0577902454.USD","SGXZ99366536.SGD","IE00B0169N27.USD","LU1504937902.USD","LU0502904849.HKD","SG9999002828.SGD","LU1048588211.SGD","LU0052750758.USD","LU0828237510.HKD","LU1105468828.SGD","LU1993786604.SGD","LU2257852520.SGD","LU0593848301.USD","IE00B8L5B284.USD","SG9999001093.SGD","LU0143863784.USD","LU1951186391.HKD","LU0501845795.SGD","LU1023057109.AUD","LU1196710864.SGD","LU0577902538.SGD","IE0003895053.USD","LU0261950983.USD","LU0048580855.USD","LU1152091754.HKD","SG9999001903.USD","BK1517","LU1481107354.HKD","LU0417516902.SGD","IE00B97KM107.HKD","80883","LU0264606111.USD","BK4588","LU0672654166.SGD","LU2097828557.USD","LU0918141887.USD","LU2097828714.EUR","LU0229945570.USD","LU1282649067.USD","LU1366334651.USD","IE00B0169L03.USD","LU0700851271.USD","BK1516","LU0047713382.USD","LU0149721374.USD","LU0029874905.USD","LU0049112450.USD","HK0000352291.HKD","HK0000306685.HKD","LU0786609619.USD","LU0737861699.HKD","LU0509642566.USD","LU0823413587.USD","SGXZ90724238.SGD","LU0823426480.USD","LU2362540622.SGD","LU1282651048.USD","LU0541502299.USD","LU0540923850.HKD","LU0259732245.USD","LU2237443622.USD","SG9999015978.USD","SG9999000327.SGD","LU0254981946.USD","LU0348825331.USD","LU2362541513.USD","LU2133065610.SGD","LU1226287529.USD","SG9999003461.SGD","SG9999002463.SGD","LU0784639295.USD","IE0008368411.USD","LU0210526637.USD","LU2462611646.USD","LU0577902298.EUR","LU0651946864.USD","LU2237443465.HKD","LU1734074674.USD","BK4581","LU2476274720.SGD","LU0048388663.USD","LU0096374516.USD","LU0149534421.HKD","LU0289960550.SGD","LU1515016050.SGD","LU0048597586.USD","LU1051769294.HKD","LU1226288170.HKD","LU0823040885.USD","LU0561508036.HKD","LU2237443382.USD","IE0008368742.USD","LU1044875133.USD","LU1328615791.USD","LU0543330566.HKD","HTCD.SI","LU2177674079.SGD","LU0878004406.USD","LU0979878070.USD","SG9999018865.SGD","LU0516422952.EUR","LU1868838027.USD","LU0414403682.SGD","LU0072913022.USD","SG9999004220.SGD","LU0348783662.USD","LU0588545490.SGD","LU0269904917.USD","BK1614","IE0003851619.USD","LU0823041008.USD","LU0181495838.USD","LU0359202008.SGD","GB00BDT5M118.USD","LU0072462343.USD","LU1769817179.HKD","LU1831875114.USD","LU0588546209.SGD","IE00BF5LJ272.USD","SG9999013353.USD","LU1810669033.SGD","LU0642271901.SGD","LU1051768304.USD","LU1568876251.USD","LU0117844026.USD","LU1917777945.USD","LU0359201885.HKD","BK1608","BK1615","SG9999001846.SGD","LU2237443895.HKD","LU0608807433.USD","IE00BZ08YT58.USD","LU1794554557.SGD","LU1048484197.HKD","IE00BZ08YS42.EUR","LU0067412154.USD","BK1163","LU1883866441.USD","LU0873338254.USD","LU1044876610.USD","LU1880383366.USD","LU0203345920.USD","LU0541501648.USD","SG9999017495.SGD","09926","LU1046422090.SGD","SG9999001226.SGD","LU0211331839.USD","LU2265009873.SGD","LU1981816686.USD","LU2106854487.HKD","LU1008478684.HKD","LU0828238088.HKD","LU0117841782.USD","LU0634319403.HKD","TCEHY","IE0031814852.USD","LU0210527791.USD","IE00B031HY20.USD","LU0210533765.USD","HK0000320223.HKD","SG9999014674.SGD","LU1568876335.HKD","LU0588545904.SGD","LU0261947096.USD","LU2051468812.USD","SGXZ81514606.USD","IE00B3M56506.USD","LU0188438112.USD","LU0862451837.USD","LU0244354667.USD","LU1770036033.HKD","LU1152091168.USD","LU1242518931.SGD","LU1323998911.USD","LU0823039010.USD","LU2399975544.HKD","LU0531970944.HKD","HK0000914686.HKD","LU0054450605.USD","LU0143863198.USD","LU0516423174.USD","BK1591","LU0329678337.USD","LU2247934214.USD","LU0348814723.USD","LU0823397285.USD","HK0000914660.USD","LU0985320562.USD","LU0326948709.USD","LU0819123356.HKD","LU0320764243.SGD","LU0737861772.HKD","BK4077","IE00BQXX3C00.GBP","BK1610","LU1719994722.HKD","LU0823038988.USD","LU2778985437.USD","LU2293587155.HKD","SG9999006514.SGD","BK1095","LU1235295612.USD","LU0327786744.USD","HK0000306701.USD","LU1064131003.USD","LU1807302812.USD","LU2242644610.SGD","LU0328353924.USD","IE0009570106.USD","LU1733274390.USD","03033","LU0898667661.SGD","SG9999002562.SGD","00700","LU0080751232.USD","SGXZ51526630.SGD","LU0499858602.USD","LU2023250504.SGD","LU1251922891.USD","LU0214875030.USD","LU0315178854.USD","LU0708995153.HKD","LU1770034418.SGD","LU0106252389.USD","LU0531971595.HKD","LU0499858438.USD","LU1720050803.USD","LU0320764599.SGD","LU0054237671.USD","LU1956131251.USD","LU0164872284.USD","BK1238","IE00B0JY6N72.USD","LU1688375341.USD","LU0456842615.SGD","LU1974910355.USD","LU0165289439.USD","LU3063872942.SGD","LU0307460666.USD","LU0070217475.USD","LU1044874839.SGD","BK1589","LU1064130708.USD","LU1769817096.USD","LU0348788117.USD","LU2226246903.HKD","LU2097828631.EUR","BK4585","LU2152927971.USD","LU0417516738.SGD","BK1609","LU0819121731.USD","SG9999000418.SGD","LU1328277881.USD","LU0823397103.USD","LU0314109678.HKD","LU0605514214.HKD","LU0140636845.USD","BK1526","LU1048596156.SGD","SG9999014914.USD","LU0516422440.USD","LU0320764755.SGD","LU0577902371.SGD","LU1282651121.HKD","LU0572940350.SGD","SG9999001069.SGD","LU2449936058.SGD","LU1655091459.SGD","SG9999018857.SGD","LU2476274308.USD","LU0791591158.USD","LU1211504680.USD","LU0384037296.USD","SG9999014880.SGD","LU1366334578.USD","SG9999006597.SGD","LU1960683339.HKD","LU2125910849.SGD","LU0856984785.SGD","LU0797268264.HKD","LU0594300419.USD","LU1725190679.HKD","LU1316542783.SGD","LU0455707207.USD","LU1808992512.USD","BK1531","BK1528","SGXZ31699556.SGD","LU0127658192.USD","LU1785774172.SGD","LU1102505929.USD","LU0683595622.HKD","LU2097828474.EUR","IE0034224299.USD","LU0651947912.USD","IE00B5MMRT66.SGD","LU0607220059.USD","LU0345769128.USD","LU0043850808.USD","LU2087589342.USD","LU0577902611.USD","LU0192582467.USD","LU1439102457.SGD","LU0084288322.USD","LU1226288097.SGD","LU1303224171.USD","BK1618","LU0431992006.USD","LU0417516571.SGD","LU0862451753.SGD","LU1224444064.USD","LU0029875118.USD","LU2237443549.SGD","BK4550","LU0865486749.SGD","LU0469268626.HKD","IE00B29SXG58.USD","BK1521","LU0370786039.SGD","LU0196878994.USD","LU0345775950.USD","LU0039217434.USD","LU2097828805.USD","LU0175139822.USD","LU0345776255.USD","LU2237443978.SGD","LU1868837565.USD","SG9999001051.SGD","LU0203347892.USD","SG9999000459.SGD","LU0608807946.USD","LU0326950275.SGD","IE0001KFT4U8.USD","LU0708995583.HKD","LU1282648689.USD","HSTECH","IE00B031HW06.USD","LU0345769631.USD","SG9999015945.SGD","LU2362541273.HKD","LU2148510915.USD","LU0329678170.USD","LU0348735423.USD","LU0882747503.HKD","SG9999015952.SGD","LU0650527681.SGD","LU0251144936.SGD","LU0831103253.SGD","IE0032834883.USD","IE00BZ08YR35.GBP","LU0871576103.HKD","LU0128522157.USD","LU1718418525.SGD","LU2498475776.HKD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2623671793","title":"大行评级丨瑞银：康方生物去年下半年业绩逊于预期，目标价降至173.4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623671793","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623671793?lang=zh_cn&edition=full","pubTime":"2026-03-30 10:47","pubTimestamp":1774838822,"startTime":"0","endTime":"0","summary":"瑞银发表研报指，康方生物去年下半年收入按年增长50%至16.4亿元，较该行及市场预期低；净亏损由前一年同期的2.76亿元扩大至5.43亿元，同样逊于该行及市场预期。2025年全年收入按年增长44%至31亿元，净亏损由2024年的5亿元扩大至11亿元。基于2025下半年业绩，该行下调2026及2027年收入预测，并上调销售及研发开支预测，导致同期每股盈利预测由1.14元及2.73元，下调至亏损0.12元及盈利1.06元；目标价由196.5港元下调至173.4港元，维持“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260330/32110854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623678703","title":"部分创新药概念股逆市上扬 荣昌生物(09995)涨4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623678703","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623678703?lang=zh_cn&edition=full","pubTime":"2026-03-30 10:23","pubTimestamp":1774837415,"startTime":"0","endTime":"0","summary":"金吾财讯 | 部分创新药概念股逆市上扬，荣昌生物 涨4.99%，康方生物涨4.75%，诺诚健华涨3.66%，先声药业涨2.73%，远大医药涨2.65%，和黄医药涨1.37%。据人民日报从国家药监局获悉，今年截至目前，我国创新药对外授权交易总额超过600亿美元，接近2025年全年的一半。今年截至3月27日，我国共批准上市10款创新药，其中8款是中国原创新药。2025年，我国批准创新药76个，创历史新高；创新药对外授权交易总金额突破1300亿美元，同样创历史新高。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977637","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2476274308.USD","00512","LU0417516902.SGD","LU0348735423.USD","00013","LU1969619763.USD","LU1961090484.USD","LU1064131003.USD","LU0348784397.USD","BK1161","09969","LU1064130708.USD","688331","LU2148510915.USD","LU0348825331.USD","LU1720050803.USD","BK0239","LU0348827113.USD","09926","159992","BK1583","02096","LU0348767384.USD","LU2328871848.SGD","LU2778985437.USD","LU0417516738.SGD","LU0348766576.USD","LU2488822045.USD","09995","BK1191","BK1587","LU1794554557.SGD","LU2476274720.SGD","LU0540923850.HKD","BK1588","LU0634319403.HKD","IE00B543WZ88.USD","06978","BK1574","LU0561508036.HKD","LU2399975544.HKD","LU0348783233.USD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","LU0417516571.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136350270","title":"异动解读 | 康方生物盘中大涨7.36%，因出现大手买入","url":"https://stock-news.laohu8.com/highlight/detail?id=1136350270","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136350270?lang=zh_cn&edition=full","pubTime":"2026-03-30 09:58","pubTimestamp":1774835931,"startTime":"0","endTime":"0","summary":"康方生物(09926)今日盘中大涨7.36%，引起了市场的广泛关注。消息面上，康方生物在上午出现了一笔大手买入交易，成交量为5.3万股，成交价为131.0港元，涉及资金694.3万港元。这种大手买入通常表明有大资金或机构投资者在积极买入，可能反映了市场对该股票的看好，从而推动股价上涨。截至目前，该股票总成交量达157.207万股，总成交金额为2.034亿港元，显示市场交投活跃。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622610318","title":"康方生物(09926)发布年度业绩，收入同比增长43.9%至30.56亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622610318","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622610318?lang=zh_cn&edition=full","pubTime":"2026-03-26 23:14","pubTimestamp":1774538074,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康方生物 发布截至2025年12月31日止年度业绩，该集团取得收入人民币30.56亿元，同比增加43.9%;毛利24.04亿元，同比增加31.01%;研发开支15.75亿元，同比增加32.61%;年内亏损11.41亿元，每股亏损1.23元。作为全球领先的双特异性抗体公司，康方生物2025年继续在世界一流的研发方面取得显著投资进展，同时较2024年缩小了Non-IFRS年内EBITDA，从而提升了财务表现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420006.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康方生物(09926)发布年度业绩，收入同比增长43.9%至30.56亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2476274308.USD","LU0348784397.USD","LU0561508036.HKD","LU0348767384.USD","LU2399975544.HKD","LU0417516571.SGD","LU2778985437.USD","LU0348766576.USD","09926","LU1794554557.SGD","LU0348783233.USD","BK1574","BK1161","IE00B5MMRT66.SGD","LU2476274720.SGD","LU0348825331.USD","LU1961090484.USD","LU1720050803.USD","LU0634319403.HKD","IE00BPRC5H50.USD","LU0348827113.USD","LU0417516738.SGD","IE00B543WZ88.USD","LU0417516902.SGD","LU2488822045.USD","LU0540923850.HKD","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1112843274","title":"港股生物医药板块涨幅居前，康方生物涨超5%，科伦博泰生物涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1112843274","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112843274?lang=zh_cn&edition=full","pubTime":"2026-03-26 09:54","pubTimestamp":1774490076,"startTime":"0","endTime":"0","summary":"3月26日，$生物(000504)$医药板块涨幅居前，$康方生物(09926)$涨超5%，$科伦博泰(06990)$生物涨超4%，$泰格医药(03347)$、$荣昌生物(09995)$涨超3%，$药明康德(02359)$、$君实生物(01877)$等个股跟涨","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0a8a9829d43b93c325f4de1fe2adcf40","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","BK4581","LU0348783233.USD","LU0348767384.USD","09926","LU0417516571.SGD","LU0417516738.SGD","LU2778985437.USD","LU1961090484.USD","IE00B5MMRT66.SGD","LU0417516902.SGD","IE00B543WZ88.USD","BK4585","LU0348784397.USD","LU1720050803.USD","02162","09995","LU2476274720.SGD","BK1161","LU0348766576.USD","LU0561508036.HKD","LU0348827113.USD","03347","LU0348825331.USD","LU2476274308.USD","BK4588","LU0540923850.HKD","LU1794554557.SGD","LU0348735423.USD","LU2488822045.USD","LU2399975544.HKD","LU0634319403.HKD","IE00BPRC5H50.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621095723","title":"【券商聚焦】交银国际：CXO行情持续回暖 料板块估值倍数合理","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095723","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621095723?lang=zh_cn&edition=full","pubTime":"2026-03-23 10:25","pubTimestamp":1774232735,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，多重利好因素共振下，2025年以来CXO行情持续回暖。该机构建议重点关注标的细分赛道成长力、核心能力布局、盈利和订单增长能见度、地缘风险敞口及估值上升空间。基于此，该机构首推药明合联，首次覆盖并重点推荐凯莱英和康龙化成。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530","LU0634319403.HKD","BK1141","LU0348766576.USD","IE00BPRC5H50.USD","LU1115378108.SGD","BK1583","03933","LU1794554557.SGD","LU1719994722.HKD","LU2488822045.USD","01789","LU1770034418.SGD","IE00B543WZ88.USD","06160","LU0417516571.SGD","03329","BK1500","BK1207","LU0348784397.USD","LU1303224171.USD","BK1197","BK1588","LU2328871848.SGD","01099","09926","BK1161","06821","BK1593","LU2476274720.SGD","BK1574","09688","LU2399975544.HKD","BK1617","LU0417516738.SGD","LU0348735423.USD","02228","LU0417516902.SGD","BK1585","LU0307460666.USD","LU0348767384.USD","02367","LU0540923850.HKD","02196","BK1191","LU2778985437.USD","02268","LU0348827113.USD","LU2476274308.USD","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620203185","title":"【券商聚焦】中国银河：“十五五”首次将生物医药列为国家新兴支柱产业，持续发力研发创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2620203185","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620203185?lang=zh_cn&edition=full","pubTime":"2026-03-20 09:23","pubTimestamp":1773969824,"startTime":"0","endTime":"0","summary":"“十四五”规划重点关注医药创新产品产业化、医药产业化技术攻关、疫苗和短缺药品供应保障、产品质量升级、医药工业绿色低碳等五大工程，成效斐然，中国创新药获批上市数量由2015年的11款提升至2024年的92款，2024年共有22款国产化药和17款国产生物药获批上市，国产创新药占比提升至42%。“十五五”规划提出健全医疗、医保、医药协同发展和治理机制，生物医药产业首次被列为国家“新兴支柱产业”，战略定位进一步提升。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976888","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","BK0276","BK1564","BK4588","LU2045819591.USD","02268","BK4581","LU0348767384.USD","LU0561508036.HKD","LU0708995583.HKD","LU1720050803.USD","XBI","02359","LU2125910500.SGD","BK4585","LU2476274308.USD","LU0348825331.USD","LU2778985437.USD","02696","HK0000320223.HKD","SG9999014674.SGD","HK0000306685.HKD","09926","LU0052750758.USD","02162","06881","LU0348735423.USD","LU1969619763.USD","399441","LU0417516571.SGD","LU0196878994.USD","BK1588","BK1161","IE00B543WZ88.USD","LU2328871848.SGD","09995","161726","06160","BK1147","HK0000306701.USD","BK1141","LU1770034418.SGD","LU0540923850.HKD","LU2476274720.SGD","601881","LU0348766576.USD","LU2242644610.SGD","LU0307460666.USD","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619433428","title":"港股康方生物再涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619433428","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619433428?lang=zh_cn&edition=full","pubTime":"2026-03-16 11:39","pubTimestamp":1773632358,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月16日，康方生物(09926.HK)再涨超4%，截至发稿涨4.26%，报114.9港元，成交额5.29亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603163672903761.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603163672903761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0634319403.HKD","LU0348766576.USD","IE00BPRC5H50.USD","LU1794554557.SGD","LU2488822045.USD","IE00B543WZ88.USD","LU0417516571.SGD","LU1961090484.USD","LU0348784397.USD","LU0561508036.HKD","09926","BK1161","LU0348825331.USD","LU2476274720.SGD","BK1574","LU2399975544.HKD","VXUS","LU1720050803.USD","LU0417516738.SGD","LU0348735423.USD","LU0417516902.SGD","LU0348783233.USD","BK4588","LU0540923850.HKD","LU0348767384.USD","BK4585","LU2778985437.USD","LU0348827113.USD","LU2476274308.USD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619375433","title":"港股异动 | 康方生物(09926)再涨超4% 公司首款三抗AK150近日获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2619375433","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619375433?lang=zh_cn&edition=full","pubTime":"2026-03-16 11:22","pubTimestamp":1773631347,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物(09926)再涨超4%，截至发稿，涨4.26%，报114.9港元，成交额5.29亿港元。消息面上，近日，康方生物宣布其三特异性抗体新药AK150获得NMPA临床试验默示许可，用于治疗晚期恶性实体瘤。AK150是康方生物基于AI制药研发技术平台和Tetrabody多抗技术平台开发的一款全球首创的ILT2/ILT4/CSF1R三抗，也是康方生物首个进入临床阶段的三抗新药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LU1794554557.SGD","LU0540923850.HKD","LU0348825331.USD","LU2488822045.USD","LU0417516571.SGD","LU0348784397.USD","BK1161","IE00B5MMRT66.SGD","LU0348735423.USD","LU0561508036.HKD","09926","LU2399975544.HKD","IE00B543WZ88.USD","LU0634319403.HKD","LU0348767384.USD","LU0348827113.USD","LU1720050803.USD","LU0417516902.SGD","LU2778985437.USD","VXUS","LU0417516738.SGD","LU2476274308.USD","LU0348783233.USD","LU2476274720.SGD","BK1574","LU0348766576.USD","IE00BPRC5H50.USD","LU1961090484.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618923825","title":"康方生物03月11日主力净流出492.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2618923825","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618923825?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:15","pubTimestamp":1773216923,"startTime":"0","endTime":"0","summary":"03月11日, 康方生物股价跌0.09%，报收114.90元，成交金额5.9亿元，换手率0.55%，振幅3.65%，量比0.47。康方生物今日主力资金净流出492.9万元，上一交易日主力净流入2.0亿元。该股近5个交易日上涨20.57%，主力资金累计净流入1.7亿元；近20日主力资金累计净流入1.1亿元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311161626a6b7863a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311161626a6b7863a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1794554557.SGD","BK1574","LU0348766576.USD","LU0348827113.USD","BK1161","LU2476274308.USD","09926","LU2399975544.HKD","LU0561508036.HKD","IE00B543WZ88.USD","LU0417516738.SGD","LU0634319403.HKD","LU2778985437.USD","LU0348735423.USD","LU0540923850.HKD","IE00BPRC5H50.USD","LU1961090484.USD","IE00B5MMRT66.SGD","LU2488822045.USD","LU2476274720.SGD","LU0417516902.SGD","LU0348825331.USD","LU0417516571.SGD","LU1720050803.USD","LU0348784397.USD","LU0348783233.USD","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618238149","title":"康方生物三抗登场","url":"https://stock-news.laohu8.com/highlight/detail?id=2618238149","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618238149?lang=zh_cn&edition=full","pubTime":"2026-03-11 10:09","pubTimestamp":1773194940,"startTime":"0","endTime":"0","summary":"近日，康方生物宣布其全球首创的ILT2/ILT4/CSF1R三特异性抗体新药AK150获NMPA临床试验默示许可，用于治疗晚期恶性实体瘤，这也是康方生物首个进入临床阶段的三抗新药。AK150可协同靶向三个靶点，多角度解除免疫抑制，临床前动物模型显示其有肿瘤抑制作用。康方生物是抗体领域全球领先的创新药企，建立了多个技术为核心的研发创新体系，已有27个候选药进入临床。此前，其全球首创的PD-1/CTLA-4、PD-1/VEGF双抗已获批上市，此次AK150获批临床是公司在抗体领域的又一重大突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031110114597ace027&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031110114597ace027&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0417516902.SGD","IE00BPRC5H50.USD","LU1720050803.USD","IE00B5MMRT66.SGD","LU0348735423.USD","LU0417516571.SGD","LU0348825331.USD","LU2476274720.SGD","LU0348783233.USD","LU1794554557.SGD","LU2399975544.HKD","LU0348767384.USD","BK1574","LU0540923850.HKD","LU2778985437.USD","LU0417516738.SGD","IE00B543WZ88.USD","BK1161","LU0348827113.USD","LU0634319403.HKD","09926","LU0348766576.USD","LU2476274308.USD","LU0348784397.USD","LU1961090484.USD","LU0561508036.HKD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107973285","title":"港股异动 | 创新药概念股普涨，康方生物、科伦博泰生物涨超9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107973285","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107973285?lang=zh_cn&edition=full","pubTime":"2026-03-10 09:58","pubTimestamp":1773107886,"startTime":"0","endTime":"0","summary":"3月10日，创新药概念股走强，$康方生物(09926)$、$科伦博泰(06990)$生物涨超9%，$三生制药(01530)$、$亚盛医药(AAPG)$、$康诺亚(02162)$涨超5%，$海西新药(02637)$涨近4%","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3f44e86c3bddb2de2b4a93e8a962fb5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK4588","BK4585","LU2476274720.SGD","LU0348735423.USD","LU1720050803.USD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","LU0348825331.USD","LU1794554557.SGD","LU0634319403.HKD","LU0417516902.SGD","LU0348767384.USD","BK1574","BK1161","LU0348766576.USD","LU0417516571.SGD","LU2778985437.USD","LU0348827113.USD","LU0540923850.HKD","IE00B543WZ88.USD","09926","LU0348783233.USD","LU0348784397.USD","LU0417516738.SGD","LU2399975544.HKD","LU0561508036.HKD","LU1961090484.USD","06990","LU2476274308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618011096","title":"港股异动 | 康方生物(09926)早盘涨近8% 全球首创的三特异性抗体新药AK150进入临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2618011096","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618011096?lang=zh_cn&edition=full","pubTime":"2026-03-10 09:40","pubTimestamp":1773106838,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物(09926)早盘涨近8%，截至发稿，涨7.33%，报111.3港元，成交额2.76亿港元。消息面上，康方生物全球首创的三特异性抗体新药AK150（ILT2/ILT4/CSF1R三抗）获得国家药品监督管理局药品审评中心临床试验默示许可批准，开展用于治疗晚期恶性实体瘤的临床试验。公开资料显示，AK150是全球唯一在研的ILT2/ILT4/CSF1R三抗，也是康方生物首个进入临床阶段的三抗新药。AK150是康方生物基于领先的AI制药研发技术平台和Tetrabody多抗技术平台而开发的全球首创新药，是公司在多特异性抗体技术领域强劲实力的又一次见证。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3f44e86c3bddb2de2b4a93e8a962fb5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","LU0417516738.SGD","BK1161","LU0417516902.SGD","BK4588","LU0348827113.USD","VXUS","BK4585","LU1720050803.USD","LU1961090484.USD","LU2476274720.SGD","IE00B543WZ88.USD","LU0634319403.HKD","LU1794554557.SGD","LU2778985437.USD","LU0348783233.USD","LU0540923850.HKD","LU0417516571.SGD","LU0348825331.USD","LU0348735423.USD","LU2399975544.HKD","LU0348766576.USD","BK1574","LU2488822045.USD","LU0348784397.USD","09926","LU0561508036.HKD","IE00BPRC5H50.USD","LU0348767384.USD","LU2476274308.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":0.072},{"period":"1month","weight":0.2642},{"period":"3month","weight":0.2092},{"period":"6month","weight":0.2023},{"period":"1year","weight":0.6807},{"period":"ytd","weight":0.3044}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.0044},{"period":"3month","weight":-0.0363},{"period":"6month","weight":0.0277},{"period":"1year","weight":0.2087},{"period":"ytd","weight":0.0124}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康方生物科技（开曼）有限公司是一家致力于研究、开发、生产及商业化让全球病人可负担的抗体药的投资控股公司。该公司在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域。该公司的产品主要包括有用于肿瘤领域的开坦尼（卡度尼利，PD-1/CTLA-4）、依达方（依沃西，PD-1/VEGF）、莱法利（AK117，CD47）、普络西（AK109，VEGFR-2）、安尼可（派安普利，PD-1）、科泰莱（塔戈利单抗，PD-L1）和用于代谢及自免领域的伊喜宁（伊努西单抗，PCSK9）、爱达罗（依若奇单抗，IL-12/IL-23）、古莫奇单抗（AK111，IL-17）。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003338},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019031},{"month":3,"riseRate":0.5,"avgChangeRate":0.006875},{"month":4,"riseRate":0.833333,"avgChangeRate":0.056366},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.003133},{"month":6,"riseRate":0.666667,"avgChangeRate":0.133235},{"month":7,"riseRate":0.5,"avgChangeRate":0.087867},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007754},{"month":9,"riseRate":0.5,"avgChangeRate":0.036209},{"month":10,"riseRate":0.5,"avgChangeRate":0.046029},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"康方生物","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康方生物,09926,康方生物股票,康方生物股票老虎,康方生物股票老虎国际,康方生物行情,康方生物股票行情,康方生物股价,康方生物股市,康方生物股票价格,康方生物股票交易,康方生物股票购买,康方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}